Keywords: revlimid, gets, orphan, drug, status, mds, eu
Revlimid gets Orphan Drug status for MDS in EU
Article | 15 March 2004
Celgene Corp's immunomodulatory drug Revlimid (CC-5013) has been awarded Orphan Medicinal Product designation by the European Commission for the treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
